We detected evidence of in-vivo cross presentation of immunogenic shared melanoma tumor antigens, and stimulation of tumor antigen-specific type I, activated, CD4+ and CD8+ T cell responses at baseline that were augmented with ipilimumab therapy in the blood. Here, CD8A is linked to melanoma.